A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 785-791

  Kouroussis, Charalambos ^a   Agelaki, Sophia ^a   Mavroudis, Dimitris ^a   Kakolyris, Styliano ^a   Androulakis, Nick ^a   Kalbakis, Kostas ^a   Souglakos, John ^a   Mallas, Kostas ^a   Bozionelou, Vassiliki ^a   Pallis, Athanasios ^a   Adamtziki, Helen ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Breast cancer; Docetaxel; Lung cancer; Oxaliplatin

Indexed keywords

DOCETAXEL; METHYLPREDNISOLONE; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAMNESIS; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LACRIMATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; TAXOIDS;

EID: 0037235867     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Giaccone G: New drugs for the management of lung cancer. Br J Hosp Med 55: 634-638, 1996.
2. Shepherd F, Gralla R, Ramlau R et al: Randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum based chemotherapy. Eur J Cancer 35(suppl 4): 247 (abstr 979), 1999.
3. Fossela VF, Devore R, Kerr NR, Crawford J et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinumcontaining chemotherapy regimens. J Clin Oncol 18(12): 2354-2362, 2000.
4. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1: 247-256, 1995.
5. Ravdin PM and Valero V: Review of docetaxel (taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 22 (2, suppl 4): 17-21, 1995.
6. Fumoleau P: Treatment of patients with liver metastases. Anticancer Drugs 7 (suppl 2): 21-33, 1996.
7. Fossela FV, Lee JS, Murphy WK et al: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12: 1238-1244, 1994.
8. Gerny T, Kaplan S, Pavlidis N et al: Docetaxel (Taxotere) is active in non-small cell lung cancer. A phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70: 384-387, 1994.
9. Fossela FV, Lee JS, Shin DM et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645-651, 1995.
10. Nabholtz JM, Pienkowki T, Mckey J et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21: 36a (abstr 141), 2002.
11. Jassem J, Pienkowski T, Pluzanska A et al: Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin, and Cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707-1715, 2001.
12. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
13. Georgoulias V, Papadakis E. Alexopoulos A et al: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicenter trial. Lancet 357 (No9267): 1478-1484, 2001.
14. Le Chevalier T, Brisgand D, Douillard JY et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European Multicenter Trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
15. Von Hoff DD, Schilsky R, Reichert CM et al: Toxic effects of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 63: 1527, 1979.
16. Bonomi P, Finkelstein, Ruckdeschel J, Blum R et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology group. J Clin Oncol 7: 1602-1613, 1989.
17. Gianni L, Munzone E, Capri G et al: Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
18. Holmes FA, Newman RA, Madden T et al: Schedule dependent pharmacokinetics (PK) in a phase I trial of taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer. Ann Oncol 5 (suppl 5): 197, 1994.
19. Raymond E, Chaney SG, Taamma A and Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9: 1053-1071, 1998.
20. Rixe O, Ortuzar W, Alvarez M et al: Oxaliplatin, tetraplatin, cisplatin and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52: 1855-1865, 1996.
21. Misset LJ, Chollet P, Vennin P et al: Multicentric phase II/III trial of Oxaliplatin (L-OHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): toxicity and efficacy results. Am Soc Clin Oncol 354a: 1266, 1997.
22. Ellis RE: The distribution of active bone marrow in the adult. Phys Med Biol 5: 255-258, 1961.
23. Miller AB, Hoogstraten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
24. Cole JT, Gralla RJ, Rittenberg CN et al: Defining the dose of docetaxel (Taxotere) in combination chemotherapy of non-small cell lung cancer: preserving efficacy with lower dose regimens. Am Soc Clin Oncol 465a: 1671, 1997.
25. Miller AV, Fossela VF, DeVore R, Kerr R et al: Docetaxel (D) benefits lung cancer symptoms and quality of life in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy. Am Soc Clin Oncol 491a: 1895, 1999.
26. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H and Taguchi T: Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative study. JCO 14: 1649-1655, 1996.
27. Monnet I, Brienza S, Hugret F, Voisin S et al: Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur J Cancer 34 (7): 1124-1127, 1998.
28. Garufi C, Nistico C, Brienza S, Vaccaro A et al: Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study. Ann Oncol 12 (2): 179-182, 2001.
29. Ravdin PM, Burris HA, Cook G et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
30. Belani C: Use of docetaxel and carboplatin for patients with non-small cell lung cancer. Oncology (suppl. 10); 26: 15-18, 1997.
31. Machover D, Diaz-Rubio E, deGramont A et al: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996.
32. Giannakakis Th, Ziras N, Kakolyris S et al: Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicenter phase I study. Eur J Cancer 36: 742-747, 2000.
33. Kosmidis PA, Mylonakis N, Fountzilas G et al: Paclitaxel and carboplatin in inoperable non-small cell lung cancer: A phase II study. Ann Oncol 8 (7): 697-699, 1997.